Abstract
Recruitment of healthy children for drugresearch has emerged due in part to several newAmerican laws and policies that have led to asurge in pharmaceutical research involvingchildren-subjects. In this paper, I review theethical and scientific issues and the argumentsin favor and against this new practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Best Pharmaceuticals for Children Act, Pub. L. No. 107-109 (2002).
Delany, L., Month, S., Savulescu, J., Browett, P., Palmer, S. “Altruism by Proxy: Volunteering Children for Bone Marrow Donation.” BMJ 312 (1996): 240–243.
Food and Drug Administration Modernization Act (FDAMA) of 1997, Pub. L. No. 105-115.
Freedman, B. “A Moral Theory of Informed Consent.” Hastings Center Report 5 (1979): 32–39.
Gaylin, W. “Competence: No Longer All or None.” In: Gaylin, W., Macklin, R., eds. Who Speaks for the Child? New York: Plenum Press, 1982, pp. 27–54.
Haslam, R. “Research in Children-issues of Risk and Harm.” In: Koren, G., ed. Textbook of Ethics in Pediatric Research. Malabar, FL: Krieger Publishers, 1993, pp. 25–36.
Koren, G. “A Practical Approach to Risk-benefit Estimation in Pediatric Research.” In: Koren, G., ed. Textbook of Ethics in Pediatric Research. Malabar, FL: Krieger Publishers, 1993, pp. 24–29.
Koren, G., Carmeli, D.B., Carmeli, Y.S., Haslam, R.H. “Maturity of Children to Consent to Medical Research: The Babysitter Test.” Journal of Medical Ethics 19 (1993): 142–147.
Koren, G., Kearns, G.L., Reed, M., Pons, G. “Use of Healty Children as Volunteers in Drug Studies: The Ethical Debate.” Clinical Pharmacology and Therapeutics 73 (2002): 147–152.
Ondrusek, N., Abramovitch, R., Pencharz, P., Koren, G. “Empirical Examination of the Ability of Children to Consent to Clinical Research.” Journal of Medical Ethics 24 (1998): 58–65.
Osmun, W.E. “Volunteering Children for Bone Marrow Donation: Children's Views should have been Represented in Discussion.” BMJ 313 (1996): 50.
Shirkey, H.C. “The Package Insert Dilemma.” Journal of Pediatrics 79 (1971): 691–693.
US Department of Health and Human Services. Food and Drug Administration 21 CFR Part 50 & 56. Additional safeguards for children in clinical investigations of FDA regulated products. Federal Register 66 (2001): 20589–20600.
US Department of Health and Human Services. Food and Drug Administration, 21 C.F.R. §201, §312, §314 and §601. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients, Part II, final rule. Federal Register 63 (1998): 66632–66671.
World Medical Association (W.M.A.). Declaration of Helsinki: Ethical principles for medical research involving human subjects. As adopted by the 18th W.M.A., Helsinki, Finland, 1964. The declaration has been amended multiple times: by the 29th W.M.A., Tokyo, Japan, 1975, the 35th W.M.A., Venice, Italy, 1983, the 41st W.M.A., Hong Kong, China, 1989, the 48th W.M.A. Somerset West, Republic of South Africa, 1996, the 52nd W.M.A., Edinburgh, Scotland, 2000, and the WMA General Assembly, Washington 2002 (Visited January 19, 2003) <http://www.wma.net/e/policy/17cnote.pdf>.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koren, G. Healthy Children As Subjects in Pharmaceutical Research. Theor Med Bioeth 24, 149–159 (2003). https://doi.org/10.1023/A:1024694828858
Issue Date:
DOI: https://doi.org/10.1023/A:1024694828858